CCL2 and prostate cancer: In turn, the upregulated CCL2 promotes STAT3 phosphorylation, leading to enhanced epithelial–mesenchymal transition (EMT) and metastasis of prostate cancer cells, thus promoting prostate cancer cell castration resistance [39].